ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
122.031,58
0,00%
S&P 500
5.283,40
0,11%
US Dollar vs BRL
5,2476
-0,06%
Bitcoin
68.946,73
0,21%
Brent Oil
77,125
-1,30%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Apogee Therapeutics Inc (APGE)

  7. Apogee Therapeutics Inc (APGE) Notícias

APGE

Apogee Therapeutics (APGE)

Apogee Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:APGE
DataHoraFonteTítuloCódigoCompanhia
30/05/202421:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:APGEApogee Therapeutics Inc
30/05/202421:05Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:APGEApogee Therapeutics Inc
28/05/202408:36Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:APGEApogee Therapeutics Inc
28/05/202408:35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APGEApogee Therapeutics Inc
28/05/202408:30GlobeNewswire Inc.Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MDNASDAQ:APGEApogee Therapeutics Inc
23/05/202408:30GlobeNewswire Inc.Apogee Therapeutics to Participate in Upcoming June Investor ConferencesNASDAQ:APGEApogee Therapeutics Inc
15/05/202417:01GlobeNewswire Inc.Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory DiseasesNASDAQ:APGEApogee Therapeutics Inc
13/05/202408:26Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:APGEApogee Therapeutics Inc
13/05/202408:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:APGEApogee Therapeutics Inc
13/05/202408:00GlobeNewswire Inc.Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial ResultsNASDAQ:APGEApogee Therapeutics Inc
06/05/202409:00GlobeNewswire Inc.Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare ConferenceNASDAQ:APGEApogee Therapeutics Inc
25/03/202408:00GlobeNewswire Inc.Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory DiseasesNASDAQ:APGEApogee Therapeutics Inc
12/03/202417:01GlobeNewswire Inc.Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 MillionNASDAQ:APGEApogee Therapeutics Inc
11/03/202407:01Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:APGEApogee Therapeutics Inc
08/03/202402:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:APGEApogee Therapeutics Inc
07/03/202420:49GlobeNewswire Inc.Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public OfferingNASDAQ:APGEApogee Therapeutics Inc
07/03/202420:27Edgar (US Regulatory)Form S-1MEF - Registration adding securities to prior Form S-1 registration [Rule 462(b)]NASDAQ:APGEApogee Therapeutics Inc
05/03/202418:23GlobeNewswire Inc.Apogee Therapeutics, Inc. Announces Proposed Underwritten Public OfferingNASDAQ:APGEApogee Therapeutics Inc
05/03/202418:05Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:APGEApogee Therapeutics Inc
05/03/202408:15Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:APGEApogee Therapeutics Inc
05/03/202408:10GlobeNewswire Inc.Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:APGEApogee Therapeutics Inc
05/03/202408:00GlobeNewswire Inc.Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of SchNASDAQ:APGEApogee Therapeutics Inc
04/03/202418:01GlobeNewswire Inc.Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024NASDAQ:APGEApogee Therapeutics Inc
02/01/202409:30GlobeNewswire Inc.Apogee Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:APGEApogee Therapeutics Inc
13/11/202309:30GlobeNewswire Inc.Apogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial ResultsNASDAQ:APGEApogee Therapeutics Inc
30/10/202309:00GlobeNewswire Inc.Apogee Therapeutics to Participate in Upcoming November Investor ConferencesNASDAQ:APGEApogee Therapeutics Inc
27/09/202309:42GlobeNewswire Inc.Apogee Announces Two Abstracts Accepted for Presentation at the 2023 European Academy of Dermatology and Venereology (EADV) CongressNASDAQ:APGEApogee Therapeutics Inc
14/09/202308:30GlobeNewswire Inc.Apogee Therapeutics to Participate at the 2023 Stifel Virtual I&I DayNASDAQ:APGEApogee Therapeutics Inc
29/08/202309:00PR Newswire (US)Paragon Therapeutics Recognizes Key Milestones and Leadership Appointment for First Spinout, Apogee TherapeuticsNASDAQ:APGEApogee Therapeutics Inc
28/08/202308:30GlobeNewswire Inc.Apogee Highlights Corporate Progress and Reports Second Quarter 2023 Financial ResultsNASDAQ:APGEApogee Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:APGE

Seu Histórico Recente

BIT
F28684
Vontobel Financial Produ...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados